Astrazeneca says Catalent deal shows importance of in-house capacity
08/02/2024 09:53
LONDON, Feb 8 (Reuters) - Astrazeneca AZN.L on
Thursday said the sale of contract drugmaker Catalent CTLT.N
to the parent of Novo Nordisk NOVOb.CO this week demonstrates
the importance of building an independent supply chain.
AstraZeneca is a client of Catalent for some of its drug
manufacturing, but AstraZeneca is working to boost its in-house
capacity to cut reliance on contract drugmakers, Chief Executive
Pascal Soriot told reporters after the release of fourth-quarter
results.
(Reporting by Maggie Fick in London and Eva Mathews in
Bengaluru
Editing by David Goodman
)
((maggie.fick@thomsonreuters.com; +44 7890 916706;))
Recent news on Catalent
See all newsBrief: Novo Holdings Completes Acquisition Of Catalent
Novo Nordisk rises as Catalent deal in US nears
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
Brief: Catalent And Novo Holdings Fulfill All Regulatory Closing Conditions For Pending Transaction
Brief: Novo Nordisk Says All Regulatory Closing Conditions Relating To Review Of Novo Holdings A/S's Pending Acquisition Of Catalent Have Been Fulfilled